WallStreetZenWallStreetZen

NASDAQ: RNAZ
Transcode Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for RNAZ

Based on 1 analyst offering 12 month price targets for Transcode Therapeutics Inc.
Min Forecast
$3.00+471.43%
Avg Forecast
$3.00+471.43%
Max Forecast
$3.00+471.43%

Should I buy or sell RNAZ stock?

Based on 1 analyst offering ratings for Transcode Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RNAZ stock forecasts and price targets.

RNAZ stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-16

1 of 1

Forecast return on equity

Is RNAZ forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.16%

Forecast return on assets

Is RNAZ forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

RNAZ revenue forecast

What is RNAZ's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$9.7M
Avg 2 year Forecast
$9.9M
Avg 3 year Forecast
$27.8M

RNAZ vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RNAZ$0.53$3.00+471.43%Buy
GOVX$1.47$120.00+8,063.27%Buy
PHIO$0.71$4.00+466.57%Buy
SXTP$0.23N/AN/A
VRPX$2.92N/AN/A
View Top Biotech Stocks

Transcode Therapeutics Stock Forecast FAQ

Is Transcode Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: RNAZ) stock is to Buy RNAZ stock.

Out of 1 analyst, 0 (0%) are recommending RNAZ as a Strong Buy, 1 (100%) are recommending RNAZ as a Buy, 0 (0%) are recommending RNAZ as a Hold, 0 (0%) are recommending RNAZ as a Sell, and 0 (0%) are recommending RNAZ as a Strong Sell.

If you're new to stock investing, here's how to buy Transcode Therapeutics stock.

What is RNAZ's revenue growth forecast for 2027-2029?

(NASDAQ: RNAZ) Transcode Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.

Transcode Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast RNAZ's revenue for 2027 to be $56,338,114, with the lowest RNAZ revenue forecast at $56,338,114, and the highest RNAZ revenue forecast at $56,338,114. On average, 1 Wall Street analysts forecast RNAZ's revenue for 2028 to be $57,499,725, with the lowest RNAZ revenue forecast at $57,499,725, and the highest RNAZ revenue forecast at $57,499,725.

In 2029, RNAZ is forecast to generate $161,463,873 in revenue, with the lowest revenue forecast at $161,463,873 and the highest revenue forecast at $161,463,873.

What is RNAZ's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: RNAZ) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is RNAZ's Price Target?

According to 1 Wall Street analyst that have issued a 1 year RNAZ price target, the average RNAZ price target is $3.00, with the highest RNAZ stock price forecast at $3.00 and the lowest RNAZ stock price forecast at $3.00.

The Wall Street analyst predicted that Transcode Therapeutics's share price could reach $3.00 by Apr 16, 2025. The average Transcode Therapeutics stock price prediction forecasts a potential upside of 471.43% from the current RNAZ share price of $0.53.

What is RNAZ's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: RNAZ) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.